Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141712 | 0.93 | TAAR1 (0.55) | TAAR1MIFCYP3A4SLC6A4CYP1A2 | |
| SCHEMBL29358232 | 0.93 | TAAR1 (0.55) | TAAR1MIFCYP3A4SLC6A4CYP1A2 | |
| SCHEMBL8992885 | 0.83 | HTT (0.51) | TAAR1MIFCYP3A4SLC6A4CYP1A2 | |
| SCHEMBL1464785 | 0.82 | CD274 (0.50) | TAAR1MIFCYP3A4SLC6A4CYP1A2 | |
| SCHEMBL7947382 | 0.76 | MMP3 (0.56) | MAPTALDH1A1PIK3CAPIK3CGPKM | |
| SCHEMBL8249225 | 0.76 | TAAR1 (0.61) | TAAR1MIFCYP3A4SLC6A4CYP1A2 | |
| SCHEMBL2119072 | 0.75 | TAAR1 (0.59) | TAAR1MIFCYP3A4SLC6A4CYP1A2 | |
| SCHEMBL5966222 | 0.75 | TAAR1 (0.55) | TAAR1MIFCYP3A4SLC6A4CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL3942500 | 0.72 | MAPT (0.46) | CYP3A4MAPTHTTALDH1A1PKM | |
| SCHEMBL50478 | 0.72 | TAAR1 (0.60) | TAAR1MIFCYP3A4SLC6A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114394-B1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS INC (US) | 2012-08-15 | — | — | EP | claimed |
| US-7777060-B2 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | claimed |
| EP-2114394-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008100301-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| US-20080194680-A1 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | claimed |
| EP-2114394-B1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-7777060-B2 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2114394-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008100301-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194680-A1 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194680-A1 | Platinum analogs with bis-nitrile-containing ligands | PCNA, LIG4, TOP2B | TAAR1 1109/4885MIF 2033/4885CYP3A4 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.